5-Amino-1MQ 'Dosing': What Vendors Claim and Evidence Supports

5-amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). It is not a peptide, despite frequently being sold alongside peptide products in the research-chemical and "biohacking" supplement markets. It has no FDA-approved use for any indication, human or animal, and it is not included on the FDA's 503A bulk drug substances list used for pharmacy compounding (FDA bulk substances list). For a fuller regulatory picture, see our FDA status tracker and the general peptide status tracker.

The question this page answers is narrow but important: when a product listing or forum thread gives you a specific dose in milligrams, what is that number actually based on? The honest answer is that it is not based on a human trial, because none has been published.

Is there a human clinical trial establishing a dose?

No. A search of the available pharmacology and mechanism literature on 5-amino-1MQ turns up cell-based enzyme assays, mouse obesity models, and a single rat pharmacokinetics paper. There is no published human Phase 1 dose-escalation study, no human safety trial, and no human efficacy trial. The rat study that does exist looked at plasma pharmacokinetics and oral bioavailability in rodents, not in people, and was designed to characterize how the compound behaves in rat blood after oral dosing, not to establish a therapeutic dose for humans (LC-MS/MS pharmacokinetic and oral bioavailability study in rat plasma).

This matters because dosing recommendations you may see on vendor sites, in supplement forums, or in influencer content did not come from that paper or any other cited study. They appear to be numbers that circulated informally and then got repeated until they looked established. Repetition is not evidence.

What do the mouse studies actually show, and why can't their doses be scaled to people?

The foundational mouse work found that a small-molecule NNMT inhibitor closely related to or including 5-amino-1MQ reversed high-fat-diet-induced obesity and improved metabolic markers in mice given the compound at researcher-determined doses over defined periods (Selective and membrane-permeable NNMT inhibitors reverse high fat diet-induced obesity in mice; A small molecule NNMT inhibitor for treatment of metabolic disorders). These are legitimate, peer-reviewed findings, and they are the reason 5-amino-1MQ generated interest as a weight-loss compound in the first place. Our weight loss evidence review and mechanism explainer go into that literature in more depth.

But mouse milligram-per-kilogram doses do not translate directly into human milligram doses through simple arithmetic, and this is not a minor technicality. Rodent-to-human extrapolation fails for several concrete reasons that apply here:

• Metabolic rate differs by species. Mice have a much higher metabolic rate per kilogram than humans, so a dose that is well tolerated in a mouse is not automatically proportional to a human dose even after standard body-surface-area conversion, which itself is an approximation, not a validated fact for an untested compound.
• Oral bioavailability has only been characterized in rats, not humans. The pharmacokinetic study available is in rat plasma (rat PK and oral bioavailability). Human absorption, distribution, metabolism, and elimination of 5-amino-1MQ have not been published. A dose that produces a certain blood level in a rat may produce a very different level, or no meaningful level, in a person.
• NNMT expression and activity vary by tissue and by individual. NNMT's role in adipocyte and liver metabolism has been studied mechanistically (NNMT and cellular metabolism; glucose availability regulates NNMT expression in adipocytes), but individual variation in NNMT expression, diet, body composition, and comorbidities in humans has not been mapped against any dose-response curve because no such human study exists.
• No safety margin has been established in humans. Without a human Phase 1 trial, there is no published data on what dose causes side effects, what dose is tolerated long-term, or what the therapeutic window looks like in people. A rodent no-observed-adverse-effect level is a starting point for trial design, not a substitute for the trial itself.

Why does a "50mg twice a day" number keep showing up online?

Numbers like this appear consistently across vendor product pages and community discussion, which can make them feel validated simply through repetition. There is no published human trial in the sourced literature above that tested 50mg, or any other specific human dose, for safety or effect. If a vendor site cites a study to support a dosing claim, check whether that study was conducted in humans or in mice or rats, and whether the dose reported in the study is the same units and same species being marketed to you. In the absence of that verification, treat any specific milligram recommendation for 5-amino-1MQ as an unverified claim, not an established dose.

A verification checklist before treating any 5-amino-1MQ dose claim as credible

Use this before accepting a specific number from a product page, forum post, or influencer:

1. Species check. Does the cited study test the dose in humans, or in mice/rats? If rodent, the number cannot be treated as a human dose without a conversion study that itself has been validated, which has not happened here.
2. Study type check. Is the source a pharmacokinetic characterization study, a cell-based enzyme assay, or a clinical trial? PK and enzyme-assay papers describe how the molecule behaves, not what dose is safe or effective in a person.
3. Outcome check. Did the cited study measure a human safety outcome (adverse events, lab values, tolerability) or an animal weight/metabolic outcome? These are not interchangeable.
4. Formulation check. Vendor products vary in purity, form, and whether they are even accurately labeled, since 5-amino-1MQ sold outside a regulated pharmacy supply chain has no FDA oversight of content or contaminants.
5. Source transparency check. Can you trace the dosing claim to a specific PMID or trial registry entry, or does it just say "studies show"? If you cannot find the primary source, assume there isn't one supporting that specific number.

If a product or article fails two or more of these checks, the dose being recommended should not be treated as evidence-based.

What is established, what is plausible, and what is not established

Established: 5-amino-1MQ inhibits NNMT in enzymatic and cell-based assays (rapid assay for NNMT substrates and inhibitors; noncoupled fluorescent NNMT activity assay), and NNMT inhibition altered metabolic outcomes in high-fat-diet mouse models (mouse obesity reversal study). Rat plasma pharmacokinetics have been characterized in a single published study (rat PK study).

Plausible but unproven: that NNMT inhibition produces comparable metabolic benefits in humans at some dose. This is a reasonable hypothesis given the mechanism and the animal data, but it has not been tested in a published human trial.

Not established: any specific human dose, human safety profile, human efficacy for weight loss or any other outcome, drug interactions in humans, or long-term effects of repeated use in people. Claims implying otherwise are not supported by the sourced literature.

What should someone do if they are already considering this compound?

Given the absence of human trial data, there is no dosing instruction that can responsibly be given here, and none should be taken from a vendor listing either. Anyone with a metabolic condition, anyone on other medications, or anyone pregnant or breastfeeding should be especially cautious given the complete absence of human safety data, and should discuss any research-chemical use with a physician rather than relying on forum consensus. For people specifically interested in medically supervised weight-loss options with an established evidence base and regulatory pathway, comparing this class of compound against GLP-1 therapies is worth doing before considering an unregulated small molecule; see our 5-amino-1MQ versus GLP-1 comparison. For a broader look at where this compound sits relative to other NNMT-pathway compounds, see our 5-amino-1MQ versus berberine comparison and the oral bioavailability page for more detail on the rat PK data referenced above.

Common questions

Does a higher dose work faster or better? There is no human dose-response data to answer this. In the absence of any human trial, statements about faster or stronger effects at higher doses are not supported by evidence and should be treated as marketing rather than pharmacology.

Is there a maximum safe dose? No maximum safe human dose has been established in any published study. This is a direct consequence of no human Phase 1 trial having been completed and reported in the literature reviewed here.

Will a rodent dose converted by body weight be safe for a person? Not reliably. Body-weight or body-surface-area conversions are used to design early human trials, not to substitute for the trials themselves, for the species-difference reasons described above.